Introduction
The novel neuropeptide orphanin FQ (OFQ), also known as nociceptin, was ®rst isolated from rat brain (Meunier et al., 1995) and porcine hypothalamus (Reinscheid et al., 1995) and has been shown to modulate opioid analgesia (Mogil et al., 1996a,b; Grisel et al., 1996; Tian et al., 1997a) and nociception (Rossi et al., 1996 Stanfa et al., 1996 Xu et al., 1996; King et al., 1997) . Mogil et al. (1996a,b) demonstrated that intracerebroventricular (i.c.v.) injection of OFQ functionally antagonizes opioid-mediated stress-induced analgesia and m-, d-and k-agonist-induced analgesia in mice. Interestingly this eect of OFQ occurs supraspinally but not spinally in mice (Grisel et al., 1996) . Recently our studies in rats have demonstrated that exogenously administered OFQ antagonizes morphine analgesia in the brain, potentiates morphine analgesia in the spinal cord (Tian et al., 1997a) , and modulates the analgesia produced by electroacupuncture (EA) (Tian et al., 1997b) . In another study OFQ administered supraspinally produced an initial hyperalgesic response followed by a delayed analgesia (Rossi et al., 1996) . Moreover, intrathecal (i.t.) OFQ produced a dose-dependent depression of a spinal nociceptive¯exor re¯ex in the rat (Xu et al., 1996) . Intrathecally administered nociceptin doserelatedly inhibited the c-®bre envoked wind-up and postdischarge of dorsal horn neurones of the rat, in vivo (Stanfa et al., 1996) . While King et al. (1997) showed that OFQ administered spinally elicited a rapidly appearing, naltrexonereversible, dose-dependent analgesia without any indication of hyperalgesia. Together these studies suggest a dual role ± analgesia versus pro-nociception ± for exogenously administered OFQ that is dependent on the site of administration.
In order to evaluate the role of endogenously released OFQ in response to the production of analgesia by EA, we have injected dierent dilutions of a rabbit anti-OFQ antibody (OFQ-Ab) i.c.v. and i.t. This approach has been widely used as a powerful technique to modify selectively the physiological activities of a target peptide. For example, this technique was used to demonstrate that in the central nervous system (CNS) the cholecystokinin octapeptide (CCK-8) plays an important role in the development of morphine tolerance and EA tolerance Han et al., 1986) . In the present study we were interested in determining whether repeated injections of morphine, or prolonged EA stimulation, would trigger the release of central OFQ and suppress morphine analgesia or EA produced analgesia. Our results suggest that i.c.v. injection of OFQ-Ab almost completely reversed acute EA tolerance, partially reversed chronic morphine tolerance and EA tolerance, but had no eect on acute morphine tolerance.
Methods

Subjects
Adult female Wistar rats weighing 200 ± 250 g were provided by the Animal Centre, Beijing Medical University. The implantation of i.c.v. cannulae or intrathecal (i.t.) catheters was performed under anaesthesia by using chlorohydrate (300 mg kg
71
). For i.c.v. cannulae, stainless steel tubing (0.8 mm outer diameter) was ®xed on the skull at stereotaxic coordinates A 5.4, L 1.5, H 3.0 mm according to the system of Pellegrino et al. (1979) . Experiments involving i.c.v. injection started 3 ± 4 days after the surgical operation.
Intrathecal (i.t.) catheterization was performed according to the method of Yaksh and Rudy (1976) . A PE-10 tube of 13 cm in length was inserted through the incised atlanto-occipital membrane and the dura into the subarachnoid space for 7.5 cm to reach the upper border of the lumbar enlargement. I.t. injections were started one day post surgery. For both types of central injections, the volume administered was 10 ml, delivered over 10 s.
Antibody microinjection
A polyclonal OFQ antiserum was raised in rabbits. Puri®cation of IgG was accomplished by pre-absorption with bovine serum albumin (BSA) and liver acetone powder followed by anity separation on a protein A column. The puri®ed IgG derived from 1.0 ml antiserum was lyophilized and stored at 7708C, and diluted in 1.0 ml sterile H 2 O as 1 : 1 OFQ-Ab. The IgG fraction from non-immunized normal rabbit serum was puri®ed as above and served as control. The OFQ antibody has no cross reactivity with dynorphin A 1 ± 17 or OFQ 1 ± 7 and mouse whole pituitary extract that contains all known forms of endorphin, b-lipotropin and dynorphin (Quigley et al., 1997) .
OFQ-Ab, as well as normal rabbit serum IgG were administered i.c.v. or i.t. in 1 : 1, 1 : 10 and 1 : 100 dilutions. I.c.v. or i.t. injection of antibody or normal serum was performed 20 min or 30 min ahead of EA stimulation or morphine administration, respectively, allowing the antibody or serum to spread through the brain or spinal cord (DellaFera et al., 1981; Fujimoto et al., 1990) .
Nociceptive testing
Experiments were performed at room temperature (20+18C). Nociception was evaluated by radiant heat tail-¯ick test (Ren & Han, 1979) . Rats were kept in a plastic restrainer with hindlimbs and tail extending. Focused light from a 12.5 W projection bulb was applied to the lower 1/3 of the tail and the tail¯ick latency (TFL) was recorded to the nearest 0.1 s. Values from the ®rst 3 measurements, with an interval of 5 min, were averaged as the basal TFL, which was usually in the range of 4 ± 6 s. TFL obtained in subsequent tests was expressed as percentage change from the basal level, with a cuto limit of 150% in order to avoid any tissue damage. In every tail¯ick test, we measured tail temperature, and if it increased more than 18C (compared with room temperature), the tail¯ick latency would be corrected by a coecient of 70.25 s 8C 71 (Ren & Han, 1979) .
Morphine tolerance
Acute morphine tolerance Rats received eight consecutive injections of morphine (5 mg kg 71 , s.c.) at 2 h intervals. Nociception was assessed 30 min after each injection by radiantheat tail¯ick assay as an index of morphine analgesia.
Chronic morphine tolerance Morphine was injected s.c. three times a day (8 h 00 min, 15 h 00 min, 22 h 00 min) for six days. The dose of morphine was 5, 10, 20, 40, 50, 60 mg kg 71 (3 times day 71 ) from day 1 to day 6, respectively. The development of tolerance was detected every day at 7 h 00 min by measuring tail¯ick latency 30 min after a challenge injection of morphine (5 mg kg 71 , s.c.).
Electroacupuncture (EA) and tolerance to analgesia produced by EA EA experiment To produce electroacupuncture analgesia (EAA) electrical stimulation was administered via stainless steel needles inserted 5 mm at two sites on the hind legs: one at the`Zusanli' point (ST36) near the knee joint (5 mm lateral to the anterior tubercle of tibia) and the other at thè Sanyinjiao' point (SP6) near ankle joint (at the level of the superior border of the medial melleolus, between the posterior border of the tibia and the anterior border of the Achilles tendon). The two needles were connected to à HANS' electronic stimulator (Beijing Aviation Institute, Beijing, China) which delivered square wave pulses of 0.3 ms pulse width, with constant current output adjustable in the range of 0 ± 3 mA and a frequency of 100 Hz. The intensity was set at 1 mA and then increased stepwise to 2 mA and then 3 mA, each of which lasted for 10 min. TFL was determined at 10, 20 and 30 min during EA stimulation, and for additional 30 min following the cessation of EA stimulation (again, at 10 min intervals).
Acute EA tolerance Rats were given continuous EA stimulation (100 Hz, 3 mA) for 6 h and antinociception in these rats was tested every hour , which was used as an index of EA tolerance.
Chronic EA tolerance EA stimulation (1, 2, 3 mA, each for 10 min) as described in`EA experiment' was given once a day (8 h 00 min) for 6 days. Each time, TFL was measured every 10 min during the 30 min EA stimulation. The mean value was used to document the development of EA tolerance.
Chemicals
OFQ antibody was provided by Dr David K. Grandy (Oregon Health Sciences University, U.S.A.). Morphine HCl is a product of Qinghai Drug House (China), dissolved in sterile normal saline (NS).
Statistical analysis
The data are expressed as the mean+s.e.mean. Group dierences were assessed by two-way analyses of variance (ANOVAs) followed by Newman-Keuls post-hoc test. P50.05 was taken as the signi®cant level of dierence.
Results
The eect of i.c.v. OFQ-Ab on the analgesia produced by 100 Hz EA
The results of a pilot study suggested that the OFQ antibody tended to increase the ecacy of 100 Hz EAA when injected i.c.v. and to suppress 100 Hz EAA after i.t. injection. We have also recently demonstrated that outbred rats display dierent degrees of analgesia (Tang et al., 1997) . Therefore, to determine whether the OFQ-Ab is able to modify the analgesia produced by 100 Hz EA, 80 rats were tested and classi®ed as either low responders (LR, increase of mean TFL less than 60% during the 30 min-EA stimulation) or high responders (HR, increase of mean TFL more than 60 %) at least one week before the antibody microinjection experiments.
Forty-seven LR rats were randomly divided into four groups, individually re-assessed for their baseline nociceptive sensitivity and then given i.c.v. injections (1 : 100, 1 : 10, 1 : 1 OFQ-Ab or 1 : 1 normal rabbit serum IgG ), respectively. Twenty minutes later, they were given 100 Hz EA as described in the Methods. Individual TFLs were assessed over a 60 min test period. As shown in Figure 1 , 100 Hz EA increased TFL in the control group by only 33.8%. In contrast the OFQ-Ab (1 : 10 and 1 : 1 dilutions) signi®cantly increased TFL by 52.4% and 76.3% (P50.05 and P50.01, respectively).
The eect of i.t. OFQ-Ab on the analgesia produced by 100 Hz EA In this experiment, we used 43 HR rats which were randomly divided into four groups of 10 ± 11 rats, each receiving 1 : 100, 1 : 10, 1 : 1 dilutions of OFQ-Ab or normal rabbit serum IgG, respectively. The i.t. injection of IgG was made 30 min before 100 Hz EA stimulation. As shown in Figure 2 , 100 Hz EA increased TFL by 63.3% in normal serum treated rats. OFQAb (1 : 10 and 1 : 1 dilutions ) signi®cantly reduced EAA (mean TFL in 60 min were 24.4% and 18.2%, respectively, P50.01).
I.c.v. OFQ-Ab failed to reverse acute morphine tolerance
For this study, seventeen rats were randomly divided into two groups (normal serum IgG group and OFQ-Ab group). All rats were given morphine (5 mg kg 71 , s.c.) every 2 h for 16 h to induce an acute tolerance to morphine analgesia. Challenge doses of morphine (5 mg kg 71 , s.c.) were given 2, 6 and 10 h after the 8th injection. OFQ-Ab or normal serum IgG were injected i.c.v. 20 min before the 1st challenge dose of morphine. As shown in Figure 3 , no signi®cant dierence was found between the two groups, indicating that the OFQ Figure 3 Eect of OFQ-Ab microinjection (i.c.v.) on the development of acute morphine tolerance. All rats were given morphine (5 mg kg 71 , s.c.) every 2 h for 16 h, followed by a challenge dose of morphine (5 mg kg 71 , s.c.) 2, 6, 10 h after the 8th injection. OFQ-Ab (n=8) or normal rabbit serum IgG (normal serum, n=9) was given 20 min before the 1st challenge dose of morphine. Tail¯ick latency (TFL) was assessed 30 min after each injection of morphine. Vertical lines represent s.e.mean. P40.05, compared with normal serumtreated group, tested by ANOVA followed by Newman-Keuls posthoc test.
antibody was not able to reverse an acute tolerance to morphine analgesia.
Reversal of tolerance to the analgesic eects of chronic morphine administration by i.c.v. OFQ-Ab
A group of 16 rats was given repeated injections of morphine (5 ± 60 mg kg 71 , s.c., t.i.d.) for 6 days to induce chronicmorphine tolerance. On day 7 the rats were evenly divided into two groups to receive either OFQ-Ab or normal serum IgG, respectively. Twenty minutes after the i.c.v. injection of antibody a test dose of morphine (5 mg kg 71 ) was given to all rats. TFLs were measured for 60 min. As shown in Figure  4 , morphine analgesia was increased by 50% in the OFQ-Abtreated group (P50.01).
Reversal of tolerance to the analgesic eects of acute EA by i.c.v. OFQ-Ab
Continuous EA (100 Hz, 3 mA) for 6 h produced tolerance in a group of 16 rats as determined by the gradual decrease in the production of analgesia ( Figure 5) . This group was then subdivided in two: one received OFQ-Ab the other normal serum IgG 40 min after the cessation of EA stimulation. All rats were given a challenge session of 100 Hz EA (3 mA, 10 min) 1, 4, 8 h after the end of 6 h EA. TFLs were measured at the termination of each 10 min EA session. EA tolerance was almost completely reversed by OFQ-Ab (P50.05) within 3 h, whereas in the normal serum IgG group the recovery was slow and incomplete during a period of 7 h ( Figure 5 ).
Reversal of tolerance to analgesic eects of chronic EA by i.c.v. OFQ-Ab
EA stimulation of 100 Hz (1, 2, 3 mA, each lasting for 10 min) was given to a group of 21 rats once a day for 6 days to induce tolerance to the analgesia produced by chronic EA. On day 7, 20 min before 100 Hz EA stimulation rats received an i.c.v. injection of either normal serum IgG (10 rats) or OFQ-Ab (11 rats). TFLs were evaluated over a 60 min test period. A reversal of tolerance to EAA was observed in the rats receiving OFQ-Ab, but not in rats receiving normal serum (P50.01, Figure 6 ).
Discussion
The recent literature describes apparently paradoxical eects of OFQ on pain modulation, i.e., analgesia in the spinal cord and pronociception in the brain. This situation is not unique to OFQ. Several other agents, such as morphine (Kayser et al., 1987; Crain & Shen, 1990) , dynorphin (Ren et al., 1985; Dickenson & Knox, 1987; Fujimoto et al., 1990) , and naloxone (Taiwo et al., 1989) , also produce paradoxical eects under certain circumstances. , s.c.) at 7h 00min every day and the TFL was measured 30 min after the morphine injection. On day 7, all rats were given a test dose (5 mg kg 71 , s.c.) of morphine. OFQAb (n=8) or normal rabbit serum IgG (normal serum, n=8) was given 20 min before morphine injection. TFL was measured for 60 min. Vertical lines represent s.e.mean. **P50.01, compared with normal serum treated group, tested by ANOVA followed by Newman-Keuls post-hoc test. Normal serum OFQ-Ab OFQ-Ab/ normal serum Figure 5 Reversal of acute EA tolerance by i.c.v. injection of OFQAb. Continuous EA (100 Hz, 3 mA) was given for 6 h. TFL was measured at the end of each hour. All rats were given a test session of EA (100 Hz, 3 mA, 10 min) 1, 4, 8 h after the cessation of EA. OFQ-Ab (n=8) or normal rabbit serum IgG (normal serum, n=8) was given 20 min before the 1st challenge of EA. Vertical lines represent s.e.mean. *P50.05, compared with normal serum-treated group, assessed by ANOVA followed by Newman-Keuls post-hoc test.
100 Hz EA, 30 min, qd Reversal of chronic EA tolerance by i.c.v. injection of OFQ-Ab. EA 100 Hz (1, 2, 3 mA, each for 10 min) was given once a day for 6 days. The % increase of TFL was measured at 10 min intervals and averaged as the index of EA analgesia. On day 7, all rats were given one session of 30 min 100 Hz EA. OFQ-Ab (n=11) or normal rabbit serum IgG (normal serum, n=10) was given 20 min before EA stimulation. TFL was measured for 60 min. Vertical lines represent s.e.mean. **P50.01, compared with normal serum-treated group, assessed by ANOVA followed by Newman-Keuls post-hoc test.
Rationale for using antibody microinjection technique for the evaluation of endogenous OFQ in CNS
Since the eects of the OFQ which seem`paradoxical' may be due to the extreme doses being used and/or the route of administration, we decided to study the role of endogenously released OFQ under physiological conditions. Since a selective antagonist for the orphan opioid-like receptor (ORL 1 ) is still lacking we used the antibody microinjection technique which has been proven to be a reliable means of selectively inhibiting/ blocking the functional activity of a given neuropeptide (DellaFera et al., 1981; Schulz et al., 1981; Carr et al., 1987; Fujimoto et al., 1990) . Although it seems that the site of action of an antibody microinjected into the lateral ventricle would be restricted mainly to super®cial layers of the ventricular wall, deeper penetration of brain tissue by antibodies has been demonstrated both morphologically (Han, 1987; Ma et al., 1992) and functionally (Della-Fera et al., 1981; Schulz et al., 1981; Carr et al., 1987; Fujimoto et al., 1990) . However, in order to control the non-speci®c action of the antiserum, 5 precautions were taken: (1) the IgG component rather than the whole antiserum was used; (2) the IgG component of normal rabbit serum was used as a control; (3) a series of dilutions of the IgG, rather than a ®xed dose, was used; (4) a ®xed volume of 10 ml for i.c.v. and i.t. injection was used; (5) the OFQ antiserum preparation shows virtually no cross-reactivity with (b-endorphin, dynorphin1-17 or OFQ1-7 (Quigley et al., 1997) .
While leakage of the OFQ antibody either from the lateral ventricle to the spinal¯uid or via a regurgitation from the spinal subarachnoid space to the supraspinal level cannot be completely ruled out, if it does occur it does not seem to be of importance since we have demonstrated the eects induced by injection of OFQ in supraspinal and spinal levels are completely opposite in direction (Tian et al., 1997a) .
Possible role for endogenously released OFQ in mediating EA analgesia Our previous ®ndings of the bidirectional modulatory eects of OFQ on morphine analgesia (Tian et al., 1997a) and EA analgesia (Tian et al., 1997b) have since been con®rmed by others (Mogil et al., 1996a,b; Grisel et al., 1996; Stanfa et al., 1996; Xu et al., 1996; King et al., 1997) . In the present study this duality was further tested by injecting OFQ antibody into the cerebral ventricle and spinal subarachnoid space, to assess whether EA analgesia could be increased by OFQ-Ab i.c.v. injection and decreased by i.t. injection.
Previous studies have shown that rats can be divided into two`groups' according to their response to standard EA stimulation (100 Hz, increasing intensity of 1-2-3 mA for a total of 30 min) (Tang et al., 1997) : rats demonstrating an increase of TFL over 60% are categorized as`high responders' (HR), while those showing an increase of TFL less than 60% are categorized as`low responders' (LR). If OFQ does exert a functional anti-opioid eect in brain and an analgesic eect in the spinal cord one might expect an OFQ antibody given i.c.v. to be able to change a LR into HR. Similarly, the i.t. injection of an OFQ antibody might change a HR rat into a LR. Both of these predictions were substantiated by our data (Figures 1  and 2 ). The present results suggest that 100 Hz EA may enhance the release of endogenous OFQ in the brain of LR rats since blockade of the actions of OFQ by the i.c.v. injection of an OFQ antibody changed LR into HR. The ®nding that HR rats could be changed into LR rats following an i.t. injection of an OFQ antibody suggests that endogenous OFQ also plays an important role in mediating 100 Hz EA analgesia in the spinal cord of HR rats.
Involvement of OFQ in the development of tolerance to morphine and EA If brain OFQ functions as an anti-opioid peptide, one might also predict that OFQ may play a role in the development of the tolerance that results after repeated administration of morphine or EA. The results, depicted in Figure 4 , suggest that chronic morphine tolerance induced by a 6 day regimen of morphine injections can be reversed signi®cantly (P50.01) albeit partially (about 50%), by the i.c.v. injection of an OFQ antibody. A similar reversal (about 50%, P50.01) of the tolerance that developed in response to chronic EA (one session per day, lasting for 30 min for 6 consecutive days) was produced by the i.c.v. injection of OFQ IgG (Figure 6 ). These results are consistent with the hypothesis that the continuous exposure of the CNS to a higher than normal concentration of opioids (either exogenously injected or endogenously released) for 6 days may trigger an increase release of OFQ, which in turn may act to reduce the ecacy of opioid-mediated analgesia.
In another experimental design when EA was administered continuously for 6 h a signi®cant degree of acute tolerance developed ( Figure 5 ). As demonstrated in previous studies, the spontaneous recovery from such acute tolerance takes about 24 h (Han et al., 1981) . This can also be seen in Figure 5 , where a slow recovery took place in the control group that received IgG obtained from normal rabbit serum. In contrast, when OFQ antibody IgG was administered i.c.v., this process of recovery was markedly accelerated suggesting that brain OFQ may have been recruited to function as an anti-opioid within a period of 6 h.
Acute tolerance to morphine analgesia was clearly produced by a regimen in which 8 injections of morphine were given over a 16 h period (Figure 3) . It is interesting to note that this type of acute morphine tolerance could not be reversed by the i.c.v. injection of OFQ antibody. One interpretation of this result is that brain OFQ is not able to aect acute morphine tolerance. The possibility that the acute tolerance that develops to morphine given repeatedly over a relatively short time period does not involve the release of OFQ in the brain suggests acute and chronic morphine tolerance are qualitatively dierent. Our further understanding of this process will greatly bene®t from the use of an antagonist of the OFQ receptor.
Since acupuncture has been shown to activate central endophin systems, the similarities between acupuncture and morphine analgesia are plain and readily explicable. However, morphine cannot substitute for acupuncture because the latter activates multiple neural pathways, leading to altered activity in numerous CNS systems (Han & Terenius, 1982) . Thus, morphine tolerance may share some similarities with EA tolerance, but they are not identical.
In conclusion, the present results suggest that brain OFQ may be partially responsible for the low responder phenotype in rats, while spinal OFQ may be an important factor in the high responder phenotype. In addition this study provides support for the hypothesis that OFQ in the brain may be an important anti-opioid peptide in the development of tolerance to opioid analgesia and electroacupuncture produced analgesia.
